Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2019
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2019
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of T-cell responses the resulting apoptosis of antigen-specific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6.
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 5, 1, 7 and 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Bladder Cancer, Colon Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Malignant Mesothelioma, Metastatic Melanoma, Myelodysplastic Syndrome, Ovarian Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Small-Cell Lung Cancer and Triple-Negative Breast Cancer (TNBC).
The latest report Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
- The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Hepatitis A virus cellular receptor 2 (HAVCR2) is a protein encoded by the HAVCR2 gene. It inhibits T-helper type 1 lymphocyte (Th1)-mediated auto- and alloimmune responses and promotes immunological tolerance. Binding to LGALS9 is proposed to be involved in innate immune response to intracellular pathogens and suppression of T-cell responses the resulting apoptosis of antigen-specific cells implicate HAVCR2 phosphorylation and disruption of its association with BAG6.
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) pipeline Target constitutes close to 25 molecules. Out of which approximately 24 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 4, 5, 1, 7 and 7 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Infectious Disease which include indications Solid Tumor, Melanoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Advanced Malignancy, Bladder Cancer, Colon Cancer, Gastric Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Head And Neck Cancer, Hematological Tumor, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Malignant Mesothelioma, Metastatic Melanoma, Myelodysplastic Syndrome, Ovarian Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Small-Cell Lung Cancer and Triple-Negative Breast Cancer (TNBC).
The latest report Hepatitis A Virus Cellular Receptor 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope
- The report provides a snapshot of the global therapeutic landscape for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
- The report reviews Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
TABLE OF CONTENTS
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Overview
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Companies Involved in Therapeutics Development
Arbele Ltd
Aurigene Discovery Technologies Ltd
BeiGene Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
GigaGen Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
Immutics Inc
Incyte Corp
Interprotein Corp
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Leads Biolabs Inc
Leidos Health
Ligand Pharmaceuticals Inc
Novartis AG
Shanghai Henlius Biotech Inc
Sutro Biopharma Inc
Symphogen A/S
Trellis Bioscience Inc
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drug Profiles
Antibody to Inhibit TIM3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGBA-425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit PD1 and TIM3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-327 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cobolimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HLX-52 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCAGN-2390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-8120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBL-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3321367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGB-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TIM-3 for Advanced Malignancy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TIM-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD366 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit HAVCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit HAVCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TIM3 for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7121661 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-1702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TIM-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sym-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit TIM-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-6061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Dormant Products
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Discontinued Products
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: Novartis to present abstract on MBG453 at American Society of Hematology Annual Meeting & Exposition (ASH) 2019
Aug 06, 2019: Curis provides update on development of mesothelioma drug candidate CA-170
May 06, 2019: Curis completes mesothelioma enrollment in CA-170 study
Jan 24, 2019: Curis: First Mesothelioma Patient Dosed in CA-170 Study
Nov 09, 2018: TESARO presents data on TSR-022 at SITC 2018 annual meeting
Oct 01, 2018: TESARO announces data presentation on its melanoma drug candidate TSR-022 at the SITC 2018 Annual Meeting
Jul 10, 2018: Selexis provides update on antibody candidate Sym023
Apr 11, 2018: Agenus Presents preclinical data on INCAGN02390 at the American Association for Cancer Research (AACR) 2018 Annual Meeting
Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress
May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting
Nov 09, 2016: Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170s Phase 1 Trial at the SITC 2016 Conference
Oct 11, 2016: Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arbele Ltd, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by BeiGene Ltd, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Hutchison MediPharma Ltd, H2 2019
Pipeline by Immutics Inc, H2 2019
Pipeline by Incyte Corp, H2 2019
Pipeline by Interprotein Corp, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Leads Biolabs Inc, H2 2019
Pipeline by Leidos Health, H2 2019
Pipeline by Ligand Pharmaceuticals Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Sutro Biopharma Inc, H2 2019
Pipeline by Symphogen A/S, H2 2019
Pipeline by Trellis Bioscience Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Overview
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Companies Involved in Therapeutics Development
Arbele Ltd
Aurigene Discovery Technologies Ltd
BeiGene Ltd
Bristol-Myers Squibb Co
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
GigaGen Inc
GlaxoSmithKline Plc
Hutchison MediPharma Ltd
Immutics Inc
Incyte Corp
Interprotein Corp
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Leads Biolabs Inc
Leidos Health
Ligand Pharmaceuticals Inc
Novartis AG
Shanghai Henlius Biotech Inc
Sutro Biopharma Inc
Symphogen A/S
Trellis Bioscience Inc
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Drug Profiles
Antibody to Inhibit TIM3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGBA-425 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Bispecific Monoclonal Antibody to Inhibit PD1 and TIM3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986258 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-170 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CA-327 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cobolimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HLX-52 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INCAGN-2390 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-8120 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBL-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3321367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGB-453 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TIM-3 for Advanced Malignancy - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit TIM-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit CD366 for Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit HAVCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit HAVCR2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides to Antagonize TIM3 for Oncology and Infectious Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-7121661 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-1702 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TIM-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Sym-023 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit TIM-3 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRL-6061 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Dormant Products
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Discontinued Products
Hepatitis A Virus Cellular Receptor 2 (T Cell Immunoglobulin And Mucin Domain Containing Protein 3 or T Cell Immunoglobulin Mucin Receptor 3 or T Cell Membrane Protein 3 or CD366 or HAVCR2) - Product Development Milestones
Featured News & Press Releases
Dec 02, 2019: Novartis to present abstract on MBG453 at American Society of Hematology Annual Meeting & Exposition (ASH) 2019
Aug 06, 2019: Curis provides update on development of mesothelioma drug candidate CA-170
May 06, 2019: Curis completes mesothelioma enrollment in CA-170 study
Jan 24, 2019: Curis: First Mesothelioma Patient Dosed in CA-170 Study
Nov 09, 2018: TESARO presents data on TSR-022 at SITC 2018 annual meeting
Oct 01, 2018: TESARO announces data presentation on its melanoma drug candidate TSR-022 at the SITC 2018 Annual Meeting
Jul 10, 2018: Selexis provides update on antibody candidate Sym023
Apr 11, 2018: Agenus Presents preclinical data on INCAGN02390 at the American Association for Cancer Research (AACR) 2018 Annual Meeting
Nov 03, 2017: Curis to Present Data On Its Cancer Drug Candidate CA-170 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
Nov 03, 2017: Curis to Present Preclinical Data On Its Cancer Drug candidate CA-327 at the Society for Immunotherapy of Cancer 32nd Annual Meeting and the Cowen IO NEXT Summit
Sep 11, 2017: Curis and Aurigene Announce CA-170 Program Update Following Data Presented at ESMO 2017
Aug 31, 2017: Curis Announces CA-170 Poster Presentation at ESMO 2017 Congress
May 25, 2017: Curis Announces Presentation on CA-170 at 2017 ASCO Annual Meeting
Nov 09, 2016: Curis Presents Early Clinical Pharmacokinetic and Biomarker Data from CA-170s Phase 1 Trial at the SITC 2016 Conference
Oct 11, 2016: Curis Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Arbele Ltd, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by BeiGene Ltd, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Eli Lilly and Co, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by GigaGen Inc, H2 2019
Pipeline by GlaxoSmithKline Plc, H2 2019
Pipeline by Hutchison MediPharma Ltd, H2 2019
Pipeline by Immutics Inc, H2 2019
Pipeline by Incyte Corp, H2 2019
Pipeline by Interprotein Corp, H2 2019
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Leads Biolabs Inc, H2 2019
Pipeline by Leidos Health, H2 2019
Pipeline by Ligand Pharmaceuticals Inc, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Shanghai Henlius Biotech Inc, H2 2019
Pipeline by Sutro Biopharma Inc, H2 2019
Pipeline by Symphogen A/S, H2 2019
Pipeline by Trellis Bioscience Inc, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019
List Of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
RELATED REPORTS
Hepatitis C Virus Envelope Protein E2 - Drugs in Development, 2021
Hepatitis C Virus Envelope Protein E2 - Drugs in Development, 2021Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 10 molecules. Out of which approximately 4 molecules are
View ReportHepatitis B (Infectious Disease) - Drugs in Development, 2021
Hepatitis B (Infectious Disease) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis B - Drugs In Development, 2021, provides an overview of the
View ReportChikungunya virus infections - Pipeline Insight, 2021
DelveInsights, Chikungunya virus infections - Pipeline Insight, 2021, report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chikungunya virus infections pipeline landscape. It covers the pipeline drug
View ReportZika Virus Infection - Pipeline Insight, 2021
DelveInsights, Zika Virus Infection - Pipeline Insight, 2021, report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Zika Virus Infection pipeline landscape. It covers the pipeline drug
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
